VENTYX BIOSCIENCES INC. - COMMON STOCK

Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis

06 Dec 2021 08:00:01 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

19 Nov 2021 08:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports Third Quarter Financial Results and Provides Business Update

17 Nov 2021 16:11:04 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

25 Oct 2021 16:58:33 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Pricing of Upsized Initial Public Offering

20 Oct 2021 20:38:40 By Nasdaq GlobeNewswire